Abstract IA04: Identification of new vulnerabilities in fusion-driven pediatric cancers with functional and chemical genomic approaches

Abstract

Abstract Fusion-driven pediatric cancers remain a therapeutic challenge. On one hand, the genomic simplicity of these malignancies and the tumor selectivity of their expressed fusion oncoproteins represent a therapeutic opportunity. These fusion oncoproteins, however, are typically transcription factors, and make for particularly challenging drug targets. Novel approaches to targeting these malignancies are needed. The EWS/ETS-driven pediatric solid tumor Ewing sarcoma is one exemplary childhood cancer. Our laboratory is integrating next-generation sequencing, functional genomic screening (shRNA and CRISPR/Cas9), and chemical genomic screening to identify, validate, and mechanistically dissect new targets in Ewing sarcoma. Emerging data from these efforts will be presented. Citation Format: Kimberly Stegmaier. Identification of new vulnerabilities in fusion-driven pediatric cancers with functional and chemical genomic approaches [abstract]. In: Proceedings of the AACR Special Conference: Pediatric Cancer Research: From Basic Science to the Clinic; 2017 Dec 3-6; Atlanta, Georgia. Philadelphia (PA): AACR; Cancer Res 2018;78(19 Suppl):Abstract nr IA04.